Iron overload was associated with an increased risk for fractures, especially hip, vertebral, and humerus fractures among men and women.

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Residents across northeastern Thailand are being encouraged to donate blood to address a significant shortage.

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

(p = 0.004 compared with baseline); LS BMD no change in Ca group [58] Observational 60 subjects with β-thalassemia major and hypogonadism (n = 30 women; age: 19 years) 17-β estradiol 50 µg ...

To prevent life-long agony, all couples must get a genetic test before planning a child, he added. Expressing concern over ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia ... with major indices like the S&P 500 ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...